Results by match-control study from HIV and uterine cervix preneoplasias in population with high and low risk (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Results by match-control study from HIV and uterine cervix preneoplasias in population with high and low risk (Meeting abstract).

Gynaecological Oncology, 8th International Meeting of the European Society of Gynaecological Oncology. June 9-12, 1993, Barcelona, Spain, 1993.. Unique Identifier : AIDSLINE ICDB/94698786
Romeo F; No affiliation given


Abstract: Since the last century, cervical carcinoma became a great medical and social problem. From the beginning studies of Rigoni-Stern to the more recent virologic and immunologic studies, the goal is still the same: find factors that can induct the disease and select risk groups. Actually all the attentions are focused on the correlation of HIV infection and onset and development of cervical carcinoma. In the last years many studies were conducted, but none of them were well randomized. The purpose of this study is to detect the correlation of HIV infection and cervical carcinoma in a match-control study conducted on two risk groups: drug abusers and prostitutes; half of them seropositive for HIV and half seronegative in women with age between 20 to 35 years old. The final data are matched with a control group. Of the 60 women, 30 women were already evaluated; 15 heavy drug abusers and 15 prostitutes. In the first group, 9 were seropositive for HIV and 6 seronegative. The positivity for CIN in the first group is: 6/9 (166-6%) and 2/6 (33.3%). In the second group, 7 were seropositive for HIV and 8 seronegative. The positivity for CIN in the second group is: 4/7 (57.1%) and 2/8 (25%). The positivity for CIN in the control group is 2/30 (0.61%). The conclusions are: (1) The positivity for HIV has a remarkable influence in the onset and development of CIN; this data is remarked by the difference in the two risk groups. (2) The role of HPV-16 in the onset of cervical pre-neoplasias is magnified by the association with HIV and probably, for this reason, cervical cancer will be enrolled in a disease connected with HIV infection. (3) Viruses infection are strongly associated with cervical preneoplasias; this comes out from the comparison from the risk groups with the control group. (4) Match-control data marks the higher incidence of CIN in an immune depressed status.
Keywords: Adult Cervical Intraepithelial Neoplasia/*COMPLICATIONS/MICROBIOLOGY Cervix Neoplasms/*COMPLICATIONS/MICROBIOLOGY Female Human HIV Infections/*COMPLICATIONS HIV Seropositivity Papillomavirus, Human/ISOLATION & PURIF ABSTRACTKWDadultcervicalintraepithelialneoplasia/KWDcomplications/microbiologycervixneoplasms/KWDcomplications/microbiologyfemalehumanhivinfections/KWDcomplicationshivseropositivitypapillomavirus,human/isolation&purifabstract
941030
M94A0895

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .